BRAF and cancer: These findings further position dogs as a powerful translational model for human and veterinary oncology, as both existing and novel targeted therapies for these mutations (e.g., PIQRAY for PIK3CA62, PLX4032 for BRAF V600E mutations63) can be assessed in canine cancer patients.